{"entity":{"id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","aka":["IPAX-3"],"tldr":"A phase 3 trial of TLX-101-Tx + Lomustine in glioma & glioblastoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.","summary":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma is a phase 3 interventional study registered as NCT07100730 by Telix Pharmaceuticals (Innovations) Pty Limited, with 50 participants planned, started 2025-11-02 and due to reach its primary completion in 2027-07. Interventions recorded: TLX-101-Tx + Lomustine and TLX101-Tx.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07100730","url":"https://clinicaltrials.gov/study/NCT07100730"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["telix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07100730","phase":"3","setting":"A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","participation":[{"nct":"NCT07100730","source":"https://clinicaltrials.gov/study/NCT07100730","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"f9850c9521e42abaa67e209bcd4442b94d581b5a613b2ca7b01558040ff55d31","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-11","leadSponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":50,"enrolmentType":"ESTIMATED","siteCount":9,"recruitingSiteCount":7,"countries":["Australia","Austria","Belgium","Netherlands"]}],"started":"2025-11-02","startedType":"actual","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07100730/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/"}]}}